A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA). (2022)
Attributed to:
Cambridge Mathematics of Information in Healthcare (CMIH)
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.17863/cam.88467
Publication URI: https://www.repository.cam.ac.uk/handle/1810/341040
Type: Journal Article/Review